reports
- Jacob Mekhael
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
UCB Publishes Fintepla LGS open-label extension results in journal
UCB announced that the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in the Epilepsy and Behavior journal. This follows previous presentations at a medical conference and highlights the long-term sustained benefit and lack of new or unexpected safety signals, which we view as supportive of Fintepla's benefit in this patient population. For reference, Fintepla is one of UCB's 5 growth drivers, and we estimate peak s...
Arcadis reports transactions under its current share buyback program
Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 14 October 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 95,177 of its own shares in the period 6 October – 10 October 2025 at an average price of €47.84. The total consideration of this repurchase was €4,552,880. The total number of shares repurchased under this program to date is 201,409 shar...
- Jacob Mekhael
UCB Publishes pyrimidine nucleo(s)(t)ide therapy results in TK2d in jo...
UCB announced the publication of results from a multicenter retrospective chart review study of pyrimidine nucleo(s)(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) in Neurology, which are in line with previous reports of the positive outcomes on survival and functional outcomes presented at a medical conference earlier this year. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 per 1m people. Doxecitine an...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
- Dirk Verbiesen
- Quirijn Mulder
Arcadis/Slow return to organic growth/HOLD
We foresee a slow return to organic growth after stagnation in 1H25. The reason is related to the ramp-up of projects like AMP8 in the UK and some major projects in Mobility. However, we are cautious on the organic growth pace as at the same time some large projects come to an end. With that, we believe 3Q25 organic growth will be 1.5%, which is in our view below what consensus has, while we remain cautious on 4Q25F as well. We think this justifies our neutral view on Arcadis despite a historic ...
- ING Helpdesk
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Lewi
Arcadis reports transactions under its current share buyback program
Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 7 October 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 106,232 of its own shares in the period 1 October – 3 October 2025 at an average price of €47.25. The total consideration of this repurchase was €5,019,428. The repurchase is in accordance with the share buyback program to reduce the capit...
UCB SA: 2 directors
Two Directors at UCB SA sold after exercising options/sold 8,000 shares at between 248.275EUR and 252.680EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...
- ING Helpdesk
Benelux Morning Notes
Acomo: Acquires Manuzzi, expanding footprint in Southern Europe ASR: Ingrid de Swart to succeed Jos Baeten as CEO of ASR in May 2026 Fagron: Antitrust clearance for Brazilian Purifarma and Injeplast deals PostNL: Relaxation USO D+3 brought forward, pre-earnings analyst call 3Q25 Sofina: Over €0.5bn of additional firepower
- Martijn Den Drijver
- ING Helpdesk
Benelux Morning Notes
Aedifica, Cofinimmo: Update on the Belgian Competition Authority. Arcadis: Share buyback programme. ASR: Focus on rural Real Estate – Farmland Fund. Coca-Cola Europacific Partners plc: Disasters strike. Heineken: From green to red. Zabka: Raising medium term store opening guidance
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Kristof Samoy
Arcadis €175m share buyback programme announced
Arcadis just announced the start of a €175m SBB. At the current share price this represents a total of approximately 4m shares or 5% of the company's ordinary shares outstanding. We applaud this move which somewhat comes as a surprise. Earlier on it was repeatedly stated by the company that M&A was the preferred way of allocating capital even at Arcadis' low trading valuation. By repurchasing shares, Arcadis is creating value while remaining well within its target leverage range of 1.5x – 2.5x N...
- Wim Lewi
Real Estate Report, Company Profiles
Over the past month, the EPRA BELUX index has underperformed (total return) the EPRA Developed Europe index by 3.2%, the STOXX50 by 5.4%, and the BEL20 by 3.6%. This underperformance relative to the EPRA Developed Europe Index can be attributed to the stronger performance of UK real estate compared to eurodenominated stocks, as UK equities led the recovery following a selloff in August. Additionally, the BELUX region had already posted strong year-to-date performance, which limited further upsid...
Arcadis announces €175 million share buyback program
Arcadis announces €175 million share buyback program PRESS RELEASE Arcadis announces €175 million share buyback program Amsterdam, 1 October 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, today announced the start of a share buyback program under which it plans to repurchase ordinary shares of Arcadis for a maximum total value of €175 million. At the current share price this represents a total of approximately 4 million shares or 5% of the company’s ordinary shares o...
Arcadis shareholders appoint Simon Crowe as new CFO and member of the ...
Arcadis shareholders appoint Simon Crowe as new CFO and member of the Executive Board PRESS RELEASE Arcadis’ shareholders appoint Simon Crowe as new CFO and member of the Executive Board Amsterdam, 30 September 2025 – Arcadis (EURONEXT: ARCAD), a global leader in sustainable design, engineering, and consultancy solutions, confirms the appointment of Simon Crowe for the position of Chief Financial Officer and member of the Executive Board. Simon Crowe was appointed to the Executive Board of Arcadis for a period of four years and will commence his role as CFO of Arcadis with immedi...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.